Likopid tablets 10mg, No. 10

The drug is used in adults in the complex therapy of diseases accompanied by secondary immunodeficiency conditions:

• acute and chronic purulent-inflammatory diseases of the skin and soft tissues, including purulent-septic postoperative complications;

• sexually transmitted infections (human papillomavirus infection, chronic trichomoniasis);

• herpes infection (including ophthalmic herpes);

• psoriasis (including psoriatic arthritis);

• pulmonary tuberculosis.

LikopidЃ is administered orally on an empty stomach, 30 minutes before meals.

Elderly patients are advised to start treatment with half doses (1/2 of the therapeutic dose), in the absence of side effects, increasing the dose of the drug to the required therapeutic dose.

If you skip taking the drug, if no more than 12 hours have passed since the scheduled time, you can take the missed dose; if more than 12 hours have passed from the scheduled time of admission, it is necessary to take only the next dose according to the scheme and not take the missed one.

Purulent-inflammatory diseases of the skin and soft tissues, acute and chronic, severe, including purulent-septic postoperative complications: 10 mg 1 time per day for 10 days;

Herpetic infection (recurrent course, severe forms): 10 mg 1 time per day for 6 days;

- for ophthalmic herpes: 10 mg 2 times a day for 3 days. After a break of 3 days, the course of treatment is repeated.

Sexually transmitted infections (human papillomavirus infection, chronic trichomoniasis):

• with human papillomavirus infection: 10 mg 1 time per day for 10 days,

• in chronic trichomoniasis: 10 mg 1 time per day for 10 days.

Psoriasis: 10-20 mg once a day for 10 days and then five doses every other day, 10-20 mg once a day.

In severe psoriasis and extensive lesions (including psoriatic arthritis): 10 mg 2 times a day for 20 days.

Pulmonary tuberculosis: 10 mg 1 time per day for 10 days.

Precautions for use

Each tablet of LikopidЃ 10 mg contains sucrose in an amount of 0.001 x.u. (bread units), which should be taken into account in patients with diabetes mellitus.

Each LicopidЃ 10 mg tablet contains 0.184 grams of lactose, which should be taken into account

patients suffering from hypolactasia (lactose intolerance, in which there is a decrease in the level of lactase in the body - an enzyme necessary for the digestion of lactose).

Active ingredient: glucosaminylmuramyl dipeptide (GMDP) - 10.0 mg.

Excipients: lactose monohydrate - 184.7 mg, sucrose (sugar) - 12.5 mg, potato starch - 40 mg, methylcellulose - 0.3 mg, calcium stearate - 2.5 mg.

- Hypersensitivity to glucosaminylmuramyl dipeptide and other components of the drug;

-pregnancy and breastfeeding; children under the age of 18;

-Autoimmune thyroiditis in the acute phase;

- conditions accompanied by febrile temperature (> 38 ? C) at the time of taking the drug;

- rare congenital metabolic disorders: alactasia, galactosemia, lactase deficiency, lactose intolerance, sucrase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption;

- use for autoimmune diseases is not recommended due to the lack of clinical data.

Pharmacological properties

Pharmacodynamics

The active substance of LikopidЃ tablets - glucosaminylmuramyl dipeptide (GMDP) - is a synthetic analogue of the structural fragment of the membrane (peptidoglycan) of bacterial cells. GMDP is an activator of innate and acquired immunity, enhances the body's defense against viral, bacterial and fungal infections; has an adjuvant effect in the development of immunological reactions.

The biological activity of the drug is realized through the binding of GMDP to the intracellular receptor protein NOD2, localized in the cytoplasm of phagocytes (neutrophils, macrophages, dendritic cells). The drug stimulates the functional (bactericidal, cytotoxic) activity of phagocytes, enhances the presentation of antigens by them, the proliferation of T and B lymphocytes, increases the synthesis of specific antibodies, and helps to normalize the balance of Th1 / Th2 lymphocytes towards the prevalence of Th1. The pharmacological action is carried out by increasing the production of key interleukins (interleukin-1, interleukin-6, interleukin-12), tumor necrosis factor alpha, gamma-interferon, colony-stimulating factors. The drug increases the activity of natural killer cells.

LikopidЃ has low toxicity (LD50 exceeds the therapeutic dose by more than 49,000 times). In the experiment, with the oral route of administration in doses 100 times higher than the therapeutic one, the drug does not have a toxic effect on the central nervous and cardiovascular systems, does not cause pathological changes in the internal organs. LikopidЃ does not have embryotoxic and teratogenic effects, does not cause chromosomal, gene mutations. In experimental studies carried out on animals, data on the antitumor activity of LikopidЃ (GMDP) were obtained.

Pharmacokinetics

The oral bioavailability of the drug is 7-13%. The degree of binding to blood albumin is weak. The time to reach the maximum concentration (tmax) is 1.5 hours after administration. The half-life (t1 / 2) is 4.29 hours. It does not form active metabolites, it is excreted mainly through the kidneys unchanged.

Overdose

Cases of drug overdose are unknown.

Based on the pharmacological properties of the drug, in case of an overdose, body temperature may rise to subfebrile (up to 37.9 ? C) values. If necessary, symptomatic therapy (antipyretic drugs) is carried out, sorbents are prescribed. The specific antidote is unknown.

Side effects

Often (1-10%) - arthralgia (joint pain), myalgia (muscle pain); at the beginning of treatment, there may be a short-term increase in body temperature to subfebrile values ??(up to 37.9 ? C), which is not an indication for discontinuation of the drug. Most often, the above side effects are observed when taking LikopidЃ tablets in high doses (20 mg).

Rarely (0.01-0.1%) - an increase in body temperature to febrile values ??(> 38.0 ? C). When the body temperature rises above 38.0 ? C, it is possible to take antipyretic drugs, which does not reduce the pharmacological effects of LikopidЃ tablets.

Very rarely (less than 0.01%) - diarrhea.

If any of the side effects indicated in the instructions are aggravated, or you notice any other side effects that are not indicated in the instructions, inform your doctor.

Interaction with other medicinal products

The drug increases the effectiveness of antimicrobial drugs, there is synergy with antiviral and antifungal drugs. Antacids and sorbents significantly reduce the bioavailability of the drug. Glucocorticosteroids reduce the biological effect of LikopidЃ.

Application during pregnancy and during breastfeeding

Taking LikopidЃ 10 mg is contraindicated in women during pregnancy and breastfeeding.

special instructions

At the beginning of taking LikopidЃ 10 mg, an exacerbation of symptoms of chronic and latent diseases associated with the main pharmacological effects of the drug is possible.

In the elderly, LikopidЃ 10 mg is used with caution, strictly under the supervision of a physician. Elderly patients are advised to start treatment with half doses (1/2 of the therapeutic dose), in the absence of side effects, increasing the dose of the drug to the required therapeutic dose.

The decision to prescribe LikopidЃ tablets 10 mg to patients with a combination of psoriasis and gout diagnoses should be made by the doctor when assessing the risk / benefit ratio, due to the potential risk of exacerbation of gouty arthritis and joint edema. If the doctor decides to prescribe LicopidЃ tablets 10 mg in a situation where the patient has a diagnosis of psoriasis and gout, treatment should be started with low doses, in the absence of side effects, increasing the dose to the therapeutic one.

Influence on the ability to drive vehicles, mechanisms

Does not affect the ability to drive vehicles and complex mechanisms.